Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 12, 2008, Pages 4721-4727

  Ono, Masami ^a   Miki, Nobuhiro ^a   Kawamata, Takakazu ^a   Makino, Rena ^a   Amano, Kosaku ^a   Seki, Toshiro ^a   Kubo, Osami ^a   Hori, Tomokatsu ^a   Takano, Kazue ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; PROGESTERONE; PROLACTIN; TESTOSTERONE;

ADULT; AGED; ANOREXIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GONAD FUNCTION; HEADACHE; HUMAN; HYPERPROLACTINEMIA; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NOSE OBSTRUCTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SOMNOLENCE; STOMACH DISCOMFORT; TREATMENT OUTCOME; VISION;

EID: 57349097676     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2758     Document Type: Article

References (29)

1. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
2. Molitch ME 1999 Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28:143-169
3. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JAH, Giustina A 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273
4. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904-909
5. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J 1995 Hyperprolactinemic amenorrhea: treatment with cabergoline vs bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 24:753-757
6. Delgrange E, Maiter D, Donckier J 1996 Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 134:454-456
7. Colao A, Di Sarno A, Sarnacchiaro F, Ferone F, Di Renzo G, Merola B, Annunziato L, Lombardi G 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876-883
8. Sarno AD, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A 2001 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256-5261
9. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P 1992 Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh) 126:489-494
10. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E, Crosignani PG, DeCecco L, Fadini R, Faglia G, Flamigni C, Tamburrano G, Ismail I, Scanlon MF 1993 The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol (Oxf) 39:323-329
11. Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338-2343
12. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G 1997 Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20:537-546
13. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G 1997 Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
14. Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammarota T, Camanni M, Camanni F 1997 Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J Endocrinol Invest 20:547-551
15. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
16. Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C, Faggiano A, Biondi B, Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325-331
17. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, DeRosa M, Zarrilli S, Lombardi G 2004 Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704-1711
18. Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF 1997 Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46:409-413
19. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A 1999 Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522
20. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509
21. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P 1992 Prolactinomas and resistance to dopamine agonists. Horm Res 38:84-89
22. Raymond V, Bealieu M, Labrie F, Boissier J 1978 Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173-1175
23. West B, Dannies PS 1980 Effects of estradiol on prolactin production and dihydroergocryptine-induced inhibition of prolactin production in primary cultures of rat pituitary cells. Endocrinology 106:1108-1113
24. Maurer RA 1982 Relationship between estradiol, ergocryptine, and thyroid hormone: effects on prolactin synthesis and prolactin messenger ribonucleic acid levels. Endocrinology 110:1515-1520
25. Gooren LJ, van der Veen EA, van Kessel H, Harmsen-Louman W, Wiegel AR 1984 Prolactin secretion in the human male is increased by endogenous oestrogens and decreased by exogenous/endogenous androgens. Int J Androl 7:53-60
26. Gillam MP, Middler S, Freed DJ, Molitch ME 2002 The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451
27. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
28. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
29. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu M-C, Betea D, Pierard L, Beckers A 2008 Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5